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Summary
Background Bakuchiol is a phytochemical that has demonstrated cutaneous antiage-
ing effects when applied topically. Early studies have suggested that bakuchiol is
a functional analogue of topical retinoids, as both compounds have been shown
to induce similar gene expression in the skin and lead to improvement of cuta-
neous photodamage. No in vivo studies have compared the two compounds for
efficacy and side-effects.
Objectives To compare the clinical efficacy and side-effect profiles of bakuchiol and
retinol in improving common signs of cutaneous facial ageing.
Methods This was a randomized, double-blind, 12-week study in which 44
patients were asked to apply either bakuchiol 05% cream twice daily or retinol
05% cream daily. A facial photograph and analytical system was used to obtain
and analyse high-resolution photographs of patients at 0, 4, 8 and 12 weeks.
Patients also completed tolerability assessment questions to review side-effects.
During study visits, a board-certified dermatologist, blinded to study group
assignments, graded pigmentation and redness.
Results Bakuchiol and retinol both significantly decreased wrinkle surface area and
hyperpigmentation, with no statistical difference between the compounds. The
retinol users reported more facial skin scaling and stinging.
Conclusions Our study demonstrates that bakuchiol is comparable with retinol in
its ability to improve photoageing and is better tolerated than retinol. Bakuchiol
is promising as a more tolerable alternative to retinol.
What’s already known about this topic?
• Bakuchiol is a plant-derived phytochemical that is known to have retinoid-like
effects in vitro.
What does this study add?
• This clinical study suggests that topical bakuchiol is similar to topical retinol in
improving facial wrinkles and pigmentation.
• Bakuchiol was better tolerated with fewer side-effects.
For centuries, botanicals were the fundamental basis of treat-
ment for various ailments.1 Even now, many well-known
medications are derived from plants. For example, aspirin is
derived from salicin, a compound found in the bark of the
willow tree,2,3 while morphine comes from Papaver somniferum,
more commonly known as opium poppy.4,5 Patients are still
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turning to botanicals and natural compounds as alternative
treatment options, providing an impetus to advance and pro-
gress the scientific knowledge regarding botanically derived
phytochemicals and compounds. One sector of growing inter-
est and research has been in cosmeceuticals, where natural
products are being evaluated for their use as cosmetic agents.6
With ageing and chronic sun exposure the skin thins, loses
elasticity and develops wrinkles, uneven pigmentation and tex-
tural irregularities.7 Common concerns regarding photoageing
include the development of wrinkles and dyspigmentation.
Currently, topical retinoids are utilized as an effective preven-
tative and therapeutic intervention.8,9 However, their signifi-
cant cutaneous side-effects are common and well documented
in the literature.10–13 These side-effects typically manifest as
cutaneous erythema, pruritus, peeling, stinging or burning,
and sensitivity.10 As the market for over-the-counter antiage-
ing products expands, the desire for retinoid-like products,
but with limited side-effect profiles, is growing.
Bakuchiol is an alternative agent to topical retinoids that has
recently gained more exposure in the literature (Fig. 1). Baku-
chiol is a purified meroterpene phenol found mainly in the
seeds of the Indian plant Psoralea corylifolia (babchi),14,15 but it
is also found in other plant sources including Psoralea glandu-
losa,16,17 Pimelea drupaceae (cherry riceflower),18 Ulmus davidiana
(Father David elm),19 Otholobium pubescens20 and Piper longum
(long pepper).21 The compound has been found to have
antiproliferative,22 anti-inflammatory,17,23–25 antioxidant26
and antiacne activity.27
Mechanistically, bakuchiol appears to target several cellular
pathways similar to those targeted by retinoids, including the
modulation of retinoic acid receptors genes and upregulation
of collagen and extracellular matrix synthesis enzymes.28
One clinical study evaluated the effect of topical bakuchiol
twice daily and found a statistically significant improvement
in wrinkles, pigmentation and firmness.28 However, this study
did not involve a control group, and it is unclear how baku-
chiol would compare clinically with topical retinoids. The goal
of this study was to compare the clinical efficacy and side-
effect profiles of bakuchiol against a commonly used retinoid,
retinol, in treating common signs of cutaneous ageing. In par-
ticular, we hypothesize that bakuchiol will have a similar effi-
cacy to retinol in the improvement of wrinkles.
Patients and methods
Study participants
This study was conducted from March to November 2017 as
a randomized, double-blinded, rater-blinded, 12-week study.
This study was approved by the institutional review board at
the University of California – Davis and registered on Clini-
calTrials.gov (NCT03112863). All participants provided writ-
ten informed consent prior to participation and received
financial compensation ($100 for the entire study). Fifty
healthy participants (age 47  72 years) were recruited and
screened for eligibility at the University of California – Davis
dermatology clinic. Participants were excluded if they were
pregnant or breastfeeding, had a known sensitivity to retinol
or bakuchiol, or had a cutaneous disease that affected the face.
Participants were also excluded if they had used isotretinoin in
the previous 6 months, had used a topical antibiotic or topical
retinoid in the 30 days prior to enrolment, or had used prod-
ucts containing salicylic acid, b-hydroxy acids or vitamins A,
C or E in the last 14 days. Current smokers and those who
had smoked within the previous 3 years (as this may serve as
a confounder in the assessment of wrinkles) and those who
had undergone a facial surgical or cosmetic procedure within
3 months prior to participation were excluded.
Study design and intervention
The study was conducted over 12 weeks and consisted of four
visits. All treatments were prerandomized using a computer-
based randomization generator with blinded allocation via
sealed envelopes. Participants were enrolled and assigned
interventions by the clinical research coordinator.
The bakuchiol used in this study was isolated from edible
seeds of P. corylifolia, a psoralene-depleted bakuchiol {INCI
name: bakuchiol; chemical name: phenol, 4-[(1E,3S)-3-ethe-
nyl-3,7-dimethyl-1,6-octadienyl], optically active} with a pur-
ity of over 99%. The topical retinol was formulated in the
same vehicle as the bakuchiol (Sytheon Ltd, Boonton, NJ,
U.S.A.).
Participants were advised to apply either the retinol or
bakuchiol in accordance with how they have been used in
previous studies. Specifically, the patients were instructed to
apply either retinol 05% cream to their full face nightly or
bakuchiol 05% cream to their full face twice daily as a thin
layer. At each visit the BTBP 3D Clarity Pro Facial Modeling
and Analysis System (Brigh-Tex BioPhotonics, San Jose, CA,
U.S.A.) was utilized to obtain high-resolution facial pho-
tographs for all study participants. The photographic instru-
mentation takes automated photographs in zero ambient
lighting with reproducible placement of the face and identical
photographic exposures. This system has been validated inFig 1. Chemical structures of (a) bakuchiol and (b) retinol.
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comparison with clinical grading of multiple facial features in
previous work.29–32 Participants were also directed to answer
a set of subjective tolerability assessment questions of the skin
at each follow-up visit. Participants were asked on a scale of 0
(none) to 3 (severe) if they had any itching, burning or sting-
ing. After completion of all study visits, a board-certified
dermatologist, blinded to study group assignment, graded
scaling, pigmentation and redness.
Facial grading and analysis
Facial photographs were analysed by a computer. Com-
puter-based grading utilized facial computational algorithms
that have been previously validated for assessment of cuta-
neous pigment, redness and wrinkles.32,33 In-person grad-
ing for pigmentation, erythema and scaling was performed
at each visit by a board-certified dermatologist and the
same grader was used throughout the study to maintain
consistency.
Tolerability assessments
Product tolerability was assessed at each follow-up, where par-
ticipants were asked to grade their experience of itching,
burning and stinging along a four-point Likert scale.
Fig 2. CONSORT flow diagram.
Table 1 Demographics of the enrolled patients
Demographic factor
Bakuchiol
group (n = 21)
Retinol group
(n = 23)
P-
value
Age (years), mean 
SD
481  15 47  16 062
Sex, male/female 2/19 1/22 –
Median baseline
erythema
1 1 006
Median baseline
hyperpigmentation
2 2 067
Erythema and hyperpigmentation were evaluated on a four-point
Likert scale.
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Statistical analysis
Previous studies have reported relevant changes in wrinkles to
be approximately 20%.34,35 An a priori power analysis showed
that there was > 90% power to detect a 20% difference in
wrinkle severity between the bakuchiol and retinol treatments
at week 12, with recruitment of at least 17 patients in each
group with alpha set to 005. Statistical analyses were per-
formed using paired t-tests (or Wilcoxon signed-rank test for
nonparametric measures) with correction for repeated mea-
sures with a Bonferroni correction. P-values < 005 were con-
sidered significant, while values between 005 and 01 were
considered a trend.
Outcomes measured
The primary outcome measure was image-analysis-based
assessment of wrinkle severity and pigmentation at 12 weeks.
Secondary outcome measures included image-based analysis of
wrinkles and facial pigmentation at earlier time points, and
redness, participant-reported tolerability (itching, burning and
stinging) and in-person clinical assessments (pigmentation,
scaling and erythema) throughout the study.
Results
Of the 50 patients who were screened, 44 met the enrolment
criteria and were randomized to receive one of the two inter-
ventions: bakuchiol or retinol. Forty-four eligible participants
were randomized into two groups: the retinol group (age 31–
55 years; 22 female and one male) and the bakuchiol group
(age 33–56 years; 19 female and two male). The CONSORT
flow diagram is shown in Figure 2. Of these patients, five
dropped out due to nonattendance to study visits, one was
lost to follow-up and unable to be contacted by the research
team, and one had to discontinue due to starting chemother-
apy. Because an intention-to-treat analysis was performed, all
44 patients were included in the analysis (mean age 44 years,
range 31–56). The demographic characteristics of each group
were similar (Table 1).
Wrinkles
Both bakuchiol and retinol significantly reduced the surface
area involvement of fine wrinkles on the face compared with
baseline (Fig. 3). Notably, significant changes from baseline
were found at the 12-week time point. There were no signifi-
cant differences between bakuchiol and retinol.
Pigmentation
Pigmentation was assessed through clinical grading and
through facial analysis of the surface area of involvement and
overall pigment intensity. Clinical grading showed that 59%
of the participants in the bakuchiol group had improvement
in their hyperpigmentation, while 44% of those in the retinol
group had improvement in their hyperpigmentation at week
12 (Fig. 4a). Retinol and bakuchiol improved both pigment
intensity (Fig. 4b) and surface area of involvement (Fig. 4c)
at week 12. There were no statistically significant differences
between bakuchiol and retinol in the facial analysis or the
clinical grading.
Adverse effects
There was significantly more scaling noted in the retinol
group at all follow-up time points (Fig. 5). Bakuchiol
appeared to show a trend towards more redness on clinical
grading at week 4 (Fig. 6a) and an increase in redness inten-
sity by computer analysis at week 4 (Fig. 6b). There were no
significant changes in redness in either group at weeks 8 or
12.
There were more subjective reports of itching and burning
in the retinol group (Fig. 7a, b), although this was not statis-
tically significant. There were more statistically significant sub-
jective reports of stinging in the retinol group (Fig. 7c).
Discussion
Our study demonstrates that bakuchiol is comparable with
retinol in its ability to improve photoageing and is better tol-
erated than retinol. Figure 8 shows facial images at baseline
and after 12 weeks of application of either retinol or baku-
chiol. In particular, for consumers who value natural products,
bakuchiol provides appeal due to its origin in several plant
species. Although retinol may also be derived from various
natural sources, much of what is on the market is manmade
and quite potent, causing unwanted side-effects.
Topical retinoids have become a staple in antiageing ther-
apy, due to their clinically proven ability to combat signs of
ageing through collagen production, inhibition of collagen
Fig 3. Participants were treated for 12 weeks with either bakuchiol or
retinol. We observed 50%, 64% and 190% decreases in fine
wrinkles surface area at 4, 8 and 12 weeks, respectively, with
bakuchiol treatment, whereas decreases of 83%, 111% and 232%
were observed at 4, 8 and 12 weeks, respectively, with retinol
treatment. *P < 005.
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degradation, angiogenesis and alteration of melanin synthe-
sis.7,36,37 The ‘retinoid reaction’ is an adverse event associated
with all topical retinoids, and is likely a result of the upregula-
tion of inflammatory mediators in the skin during therapy.38
The experiences of participants in this study are consistent
with those in previous reports, in that other study patients
also experienced burning, stinging and scaling.
Bakuchiol exhibits promise to serve as an alternative to reti-
nol with fewer side-effects. Both this study and a previous
in vivo study show that twice-daily application of bakuchiol can
lead to marked improvements in a number of antiageing
parameters.28 Although retinol and bakuchiol are structurally
different, bakuchiol has demonstrated the ability to serve as a
functional analogue to retinol. Specifically, both compounds
induce highly similar gene expression in human skin. This
includes genes involved in the cellular uptake of endogenous
retinol, the activation of retinol in the skin and the production
Fig 4. (a) Changes in the clinical grading of hyperpigmentation in comparison with baseline were assessed at 4, 8 and 12 weeks. (b) Computer-
analysis-based pigment intensity and (c) surface area were measured at 4, 8 and 12 weeks in both treatment groups. *P < 005.
Fig 5. The presence of scaling among the participants was assessed at
4, 8 and 12 weeks. *P < 005.
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of extracellular matrix proteins that provide epidermal support
and integrity.28 These molecular findings translate to clinical
outcomes, as our study shows comparable improvements in
wrinkles and hyperpigmentation with the use of either com-
pound.
Although bakuchiol may share some of its antiageing prop-
erties with retinoids, the compound induces its own set of
chemical pathways that may also contribute to its antiageing
effects. Perhaps most notably, bakuchiol influences several
antioxidant processes. Oxidative stress on skin cells, from both
internal metabolic processes and external environmental toxins
and stressors, is known to contribute significantly to cutaneous
ageing.39 Bakuchiol has been shown to activate nuclear factor
erythroid 2-related factor 2, a transcription factor that plays a
significant role in cellular resistance to oxidative stess.26,40
Additional antioxidant capabilities include its capacity for scav-
enging oxygen free radicals and its significant role in prevent-
ing mitochondrial lipid peroxidation.41–43
In addition to improving wrinkle depth, bakuchiol also
decreased pigment intensity and surface area over the 12-week
treatment course. This may be attributable to bakuchiol’s
antioxidant effects, as well as its ability to disrupt melanin
synthesis. Interestingly, bakuchiol can interfere with two steps
of the melanin synthesis pathway, blocking both a-melano-
cyte-stimulating hormone activation and tyrosinase (the rate-
limiting enzyme in melanin synthesis).21,44 Bakuchiol’s sup-
pressive effects on cutaneous melanin production prime the
compound for use in both antiageing and antihyperpigmenta-
tion cosmeceuticals.
Regarding tolerability, the patients receiving bakuchiol had
fewer adverse cutaneous side-effects than those taking retinol,
with less stinging and scaling. In addition to its antioxidant
properties, this may also be related to bakuchiol’s anti-inflam-
matory effects.23,45 Furthermore, bakuchiol has not been
Fig 6. Changes in erythema were assessed by clinical grading (a) and
by computer analysis (b) of redness intensity. Clinical grading is
reported as the percentage of the participants, whereas computer
grading is measured as the change from the baseline measurement.
Error bars represent the SEM. *P < 005.
Fig 7. Adverse effects were assessed in the participants: (a) itching,
(b) burning and (c) stinging. *P < 005.
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shown to increase photosensitivity, as retinoid products are
known to do.46 There were no reports of photosensitivity in
this study.
Interestingly, one of the patients in the bakuchiol group
noted that scaling along the hairline subsided with topical use.
While we did not evaluate for treatment of dandruff or sebor-
rhoeic dermatitis, it is notable that bakuchiol has known anti-
fungal activity.47
This study has certain limitations. The sample size is rela-
tively small and the study was done at a single centre; however,
the number of study participants is double that of early trials
for topical retinoids.48,49 Our study is limited to cosmetic eval-
uation, and no evaluations were made regarding collagen pro-
duction. While patients in the retinol treatment arm applied the
product once per day, those in the bakuchiol treatment arm
applied the product once in the morning and once in the
evening. However, this is consistent with the products’ respec-
tive standard treatment regimens outside of a clinical trial set-
ting and reflects that bakuchiol is well tolerated during daytime
use without photosensitivity. Another limitation was that seven
of the 44 enrolled participants dropped out, but we utilized an
intention-to-treat analysis to account for this. Our study was
limited to assessments over 12 weeks and an assessment of
longer time periods would need further study. Finally, our
study did not evaluate any diseases, and our results are limited
to otherwise generally healthy adults. Therefore, the results can-
not be generalized to patients with other diseases.
Overall, our results suggest that bakuchiol is an effective
option for improvement of photoageing and is a better-toler-
ated alternative to retinol. Our results warrant future studies
with an expanded population.
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